EAU 2025 | 100% Specificity Achieved! Qilu Hospital of Shandong University’s “Non-Biopsy” Prostate Cancer Study Presented as Oral Report

EAU 2025 | 100% Specificity Achieved! Qilu Hospital of Shandong University’s “Non-Biopsy” Prostate Cancer Study Presented as Oral Report

2025.03.30
Prostate biopsy remains the gold standard for diagnosing prostate cancer, but it carries risks such as infection, bleeding, and urinary obstruction. As a result, growing research interest has focused on developing “non-biopsy” diagnostic strategies. At the 2025 Annual Meeting of the European Association of Urology (EAU25), a study led by Professor Shouzhen Chen and Professor Benkang Shi from Qilu Hospital of Shandong University was selected for oral presentation. The study demonstrated that combining PSMA PET/CT, multiparametric MRI (PI-RADS score), and blood biomarkers—PHI and PSAD—can reduce the prostate cancer missed diagnosis rate to zero.
Professor Ying Fan Wins SGBCC Best Poster Award for Real-World Study on HER2-Positive Breast Cancer in the Neoadjuvant Setting

Professor Ying Fan Wins SGBCC Best Poster Award for Real-World Study on HER2-Positive Breast Cancer in the Neoadjuvant Setting

2025.03.30
The 19th St. Gallen Breast Cancer Conference (SGBCC), held in Vienna from March 12 to 15, 2025, remains one of the most influential global platforms in early breast cancer care. Among seven studies awarded the prestigious Best Poster Award, four came from China, including a multi-center real-world study led by Professor Ying Fan from the Cancer Hospital Chinese Academy of Medical Sciences. Her research focused on treatment-insensitive HER2-positive breast cancer patients undergoing neoadjuvant therapy. Oncology Frontier spoke with Professor Fan to learn more about the study’s results, and broader implications.
EAU 2025 | CUHK’s Peter Chiu and Team Highlight Advances in Precision Biopsy and Standardized Treatment for Prostate Cancer

EAU 2025 | CUHK’s Peter Chiu and Team Highlight Advances in Precision Biopsy and Standardized Treatment for Prostate Cancer

2025.03.30
Prostate cancer remains one of the most prevalent malignancies threatening men’s health worldwide. A major research focus today lies in developing accurate screening and diagnostic strategies that minimize the invasiveness and psychological burden of biopsy procedures. Landmark studies like SMART and PRECISION aim to address these challenges. At the 2025 European Association of Urology (EAU) Annual meeting, Professor Chiu Ka Fung Peter from the Department of Urology at The Chinese University of Hong Kong presented the latest findings from the SMART study. Following his presentation, Professor Chiu spoke with UroStream to share key updates in prostate cancer diagnostics and care.
2025 South-North Forum | Prof. Jin Feng: Breaking Barriers and Leading Innovation – A New Chapter in Breast Cancer Research

2025 South-North Forum | Prof. Jin Feng: Breaking Barriers and Leading Innovation – A New Chapter in Breast Cancer Research

2025.03.29
The 2025 South-North Forum – 7th Breast Cancer forum was recently held in Shanghai, co-hosted by the Shanghai Anti-Cancer Association and the China Anti-Cancer Association Committe of Breast Cancer Society(CACA-CBCS), with support from the Chinese Medical Association, Chinese Society of Oncology- Breast Oncology(CMA-CSO-BO). The event was co-organized by Fudan University Shanghai Cancer Center and The First Affiliated Hospital of China Medical University. Upholding the values of openness, collaboration, and innovation, the forum has emerged as a dynamic hub of academic exchange in breast cancer research. Oncology Frontier invited Prof. Jin Feng, chair of the forum and a leading figure from The First Affiliated Hospital of China Medical University, to reflect on the forum’s milestones, key highlights, and its role in nurturing the next generation of clinical scholars.
Professors Jeremy Teoh and Yige Bao Share Research Highlights and Clinical Insights, as “Chinese Excellence” Shines on Europe’s Academic Stage

Professors Jeremy Teoh and Yige Bao Share Research Highlights and Clinical Insights, as “Chinese Excellence” Shines on Europe’s Academic Stage

2025.03.29
With diagnostic and therapeutic technologies advancing rapidly, precision treatment strategies for genitourinary malignancies such as urothelial carcinoma and prostate cancer are evolving with growing momentum. At the recent 2025 Annual Meeting of the European Association of Urology (EAU25), Professor Jeremy Teoh of The Chinese University of Hong Kong and Professor Yige Bao of West China Hospital, Sichuan University both presented major findings or received distinguished honors, showcasing the academic strength and international influence of Chinese urologists.  UroStream invited both experts for an insightful conversation on their research, clinical progress, and evolving strategies in the treatment of urothelial and prostate cancers.
SGBCC 2025 | Dr. Man Li: Chinese Innovation is Shaping Clinical Practice and Amplifying the Voice of China on the Global Stage

SGBCC 2025 | Dr. Man Li: Chinese Innovation is Shaping Clinical Practice and Amplifying the Voice of China on the Global Stage

2025.03.29
The 19th St. Gallen Breast Cancer Conference (SGBCC 2025) took place from March 12–15, 2025, in Vienna—the world-renowned capital of music. A major highlight of the event was the “Voice of China” session, where international experts gathered to exchange insights on the development of innovative therapies from China. On this occasion, Oncology Frontier sat down with Dr. Man Li from The Second Hospital of Dalian Medical University to discuss the key drivers enabling innovative drugs to shift from late-stage to early-stage breast cancer, and to explore how Chinese innovations are increasingly shaping global clinical practice.
SGBCC Voice of China丨Dr. Yongmei Yin: Steady Progress Leads to Breakthroughs—Bridging East and West to Shape a New Era in Breast Cancer Care

SGBCC Voice of China丨Dr. Yongmei Yin: Steady Progress Leads to Breakthroughs—Bridging East and West to Shape a New Era in Breast Cancer Care

2025.03.28
The 19th St. Gallen Breast Cancer Conference (SGBCC 2025) recently concluded in Vienna, and once again, voices from China stood out on the global stage. Dr. Yongmei Yin from Jiangsu Provincial Hospital made history as the first Chinese female expert to join the St. Gallen International Consensus Panel on Early Breast Cancer, actively participating in the formulation of the consensus and highlighting China’s significant contributions to global breast cancer research. During the specially organized “Voice of China” session, Professor Yin delivered a keynote titled “Chinese Clinical Trials Transforming Breast Cancer Practice: From Local Innovation to Global Impact”, in which she presented landmark clinical research findings across breast cancer subtypes and showcased the strength of China’s clinical research. Oncology Frontier invited Professor Yin for an exclusive interview during the conference to hear her reflections on her debut as a voting panel member, key insights from her “Voice of China” presentation, and future plans for collaboration between SGBCC and CSCO.